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Abstract
Purpose: Laryngeal cancers are amongst the most common cancers affecting head and neck region. In this study, 
we analyse the overall survival (OS) following hypofractionated radiotherapy (RT) in early-stage glottic carcinoma 
treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore.
Methods: Between October 2003 and June 2009, 87 patients with early-stage glottic carcinoma were treated with 
hypofractionated RT. All patients were included in the study. The ratio of male: female is 94%:6%. Mean age was 
62 years (range 31–83 years). 66% of the patients were smokers. AJCC stage was T1a in 76%, T1b 20% and T2 in 4% 
of the patients. Histological distribution was; squamous cell carcinoma 97%, verrucous carcinoma 2% and  squamous 
cell spindle variant 1%. Median follow-up time was 59 months (range 4–122 months). RT dose was 55 Gy in 20 
fractions over a period of 4 weeks. Median RT treatment time was 28 days (range 23–35 days). Patients that lost to 
follow-up were contacted through telephone.
Results: The 10-year OS was 83%. Patterns of failure was 7 local and 1 distant while 1 patient had persistent disease. 
15 patients were dead at the time of study. Cause of death; 13 patients died due to Ischemic heart disease and 2 due to 
primary disease.
Conclusion: Hypofractionated RT 55 Gy in 20 fractions seems to achieve good OS while offering potential for 
optimizing resources usage.
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Introduction
Larynx or voice box is divided into three regions, 
supraglottis, glottis and subglottis. Amongst them, 
glottic cancers comprise 60–65%.[1] Main histology 
is the squamous cell carcinoma and almost 40% of 
the patients have Stages III and IV disease at the time 
of presentation.[2] Patients with early squamous cell 
carcinoma of the laryngeal glottis are generally considered 
to have good prognosis.[3,4] The aims of treatment for 
early glottis cancer are cure, laryngeal voice preservation, 
optimal voice quality with minimal morbidity, expense 
and inconvenience.[5] Both treatment modalities including 
surgery and radiation therapy are fairly successful in the 
management of early glottis cancers; the treatment of 
choice remains controversial as the evidence for most 
decisions is derived from non-randomised studies.[6] 
Radiation therapy has comparable cure rates for selected 
T1 and T2 early-stage glottis cancers with laser excision, 
cordectomy and hemilaryngectomy. Radiation therapy is 
preferred over surgery due to its less selection criteria, 
good quality of voice and comparable local control and 
survival rates.[3] Local control rates have ranged from 
80% to 95% for T1 and from 50% to 80% for T2 early 
glottic cancers treated with radiotherapy (RT). There is a 
range of radiation fractionation policies for the treatment 
of early laryngeal cancer worldwide. While most centres 
have adopted conventional 2 Gy fractionation for 6–7 
weeks, others use hypofractionated regimens with shorter 
overall time.[7-9]
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The traditional approach to the treatment of Stage I 
vocal cord cancer has been to deliver 66–70 Gy in 2 Gy 
daily fractions. A Japanese randomised trial compared 
hypofractionated RT at 2.25 Gy daily with 56.25 Gy for 
‘minimal’ T1 and between 63 Gy for larger T1 tumours 
with 60–66 Gy in 2-Gy fractions. Local control was 
superior with hypofractionation, and toxicity was reported 
as extremely low in both arms, leading to widespread 
adoption of the hypofractionated regimen.
The use of hypofractionation to minimise potential for 
tumour repopulation during RT is particularly important 
for early larynx in view of small field sizes, potentially 
allowing larger doses per fraction without excessive 
late morbidity.[9] There are only limited published data 
documenting the efficacy of the more hypofractionated 
schedules. Importantly, these are little data available to 
support the use of similar schedules for the treatment of 
T2 glottic carcinoma, with the two main series reporting 
the use of hypofractionated schedules with fraction sizes 
>2.5 Gy included only T1 disease.[11,12]
A study published in 2011 in International Journal of Head 
and Neck Surgery showed 5-year overall survival (OS) of 
86%.[13] Those patients were followed for another 5 years, 
and here, we report our 10-year experience of treating T1 
and T2 glottic carcinoma with 55 Gy in 20 fractions over 
a period of 4 weeks.
Methods 
The time duration for this retrospective study was between 
October 2003 and December 2014. The records of total 
87 patients with early-stage glottic carcinoma who have been 
treated with hypofractionated RT were identified through the 
head and neck database as well as the online information 
system. Hypofractionated RT was defined as the delivery of 
a smaller total RT dose in few larger fractions. All patients 
were included in the study. 94% of the patients were male 
and 6% were female. 78% belonged to Punjab while 16% 
were from Khyber Pakhtunkhwa Province.
The mean age of  the pat ients  was 62 years 
(range 31–83 years). 66% of patients were smokers.
AJCC stage-wise distribution is shown in Table 1 and 
histologic distribution is shown in Table 2, respectively.
Median follow-up duration was 59 months with a range 
of 4–122 months. RT dose was 55 Gy in 20 fractions 
over a period of 4 weeks. RT was given 5 days a week. 
21% of the patients were treated on cobalt 60 and 79% 
of the patients were treated on linear accelerator. Energy 
used was 6 MV photons. The median RT treatment time 
was 28 days (range 23–35 days). Patients who lost to 
follow-up for <2 years were contacted through telephone 
to assess the disease status. OS was defined as the time 
duration between the start of treatment to the time till 
death.
Results
The 10-year OS as determined by the Kaplan–Meir 
method was 83% [Figure 1].
Discussion
There are certain number of factors that affect the 
outcome of early glottic cancers which are related to 
patient, tumour and treatment offered. Females have 
same prognosis or even better than males in head 
and neck cancers. The reason for this observation is 
unknown. In our series, none of the five women failed 
treatment. Higher T-stage adversely impacted local 
control. AJCC staging system subclassifies T1 glottis 
cancers into two types, T1a tumour limited to one vocal 
cord (may involve anterior or posterior commissure) 
and T1b tumour involvement of both the vocal cords. 
The incidence of regional nodal metastasis in T1 glottic 
cancers ranges from 0% to 2% while it is 10–15% in 
T2 and T3, respectively.[10,11] Local control rates for T1 
Table 1: AJCC stage distribution
AJCC stage Number of patients (%) 
T1a 66 (76) 
T1b 18 (20) 
T2 3 (4) 
Table 2: Histological subtype distribution
Histologic type Number of patients (%) 
Squamous cell carcinoma 84 (97)
Verrucous carcinoma 2 (2)
Squamous cell spindle variant 1 (1)
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glottis cancer treated with radiation vary between 80% 
and 95% and with surgical salvage ultimate local control 
rates are between 90% and 100%. Patients with Stage T1b 
lesions are considered to have a lower local control rates 
compared with T1a tumours.[12,14,15] In a series covering 
449 patients, local control rates for T1a and T1b were 91% 
and 82%, respectively.[12] However, other authors have 
failed to show such difference in locoregional control 
(LRC) for T1 lesions.[5-9] The management plans for T2 
carcinoma of the glottis cancers remain controversial and 
have wide variations. In general, T2 lesions have poor 
cure rates than T1 lesions. The local control rates for T2 
squamous cell carcinoma of the glottis with conventional 
RT are approximately 71–85% and salvage rate for 
local radiation failure is 88–95%.[7] In our study, a total 
number of patients with T2 tumour were four. They were 
treated with conventional fractionation encompassing 
the primary site and upper neck with radiation treatment 
portals. Among the four patients with T2 tumours, two 
had local failure at 9 and 14 months following treatment 
that was salvaged with laryngectomy [Table 3].
Anterior commissure involvement has been reported by 
some authors to be associated with poor local control; 
however, it is controversial. A review of approximately 
2200 Stage I patients with glottic carcinoma showed 
no increase in local failure with anterior commissure 
involvement.[16,17] Other studies indicate that anterior 
commissure involvement is a poor prognostic variable 
for local control with both RT and surgery.[4-9]
Other factors associated with poor outcome in early glottic 
cancers include total dose (<65 Gy),[18,19] overall treatment 
time (>41 days), poorly differentiated histology,[20] smaller 
fraction sizes (<2 Gy vs. >2 Gy),[21] subglottic extension, 
treatment delay (>3 days),[22] treatment interruptions, age 
and smaller field size.[22] Smokers, particularly those who 
continue to smoke after treatment, are considered to have 
a worse LRC.[10]
The potential risk of prolonged overall RT treatment time 
in head and neck cancer is well documented. Prolonged 
overall RT treatment time has a negative impact on LRC 
and survival.[23] Rudoltz et al. reported 100% local control 
when RT was completed within 42 days, in contrast to 50% 
local control when treatment lasted from 55 to 66 days.[24]
Fein et al. in his study reported a lower local control 
rate when radiation was extended for <50 days in the 
management of T1–T2 glottic carcinoma.[16] Machine 
breakdown, holidays and patient-related factors are major 
causes for treatment interruptions. An audit by Royal 
College of Radiologists of radical RT for head and neck 
cancer showed that 81% of treatment interruptions were 
due to machine breakdown or servicing.[25] Local control 
rate may be affected by size of the fraction. Many studies 
have demonstrated better local control rates if fraction 
size is ≥2 Gy.[26-30] Short et al. reported 95% LRC with 
accelerated hypofractionated regimen 52.5–55 Gy over the 
period of 4 weeks compared with 75% when treating with 
60–66 Gy over the period of 6–6.5 weeks (P = 0.002).[26] 
In another study covering 171 patients, control rate was 
significantly improved using 2 Gy than 1.8 Gy/fraction.[27] 
Patients treated with higher fraction size >3 Gy have a 
higher risk of developing late complications, and this is in 
contrast to the findings of the British Institute of Radiology 
Figure 1: Patterns of failure; local 7, distant 1, while persistent 
disease in one patient, respectively. 15 patients were dead at 
the time of study. Cause of death; 13 patients due to ischemic 
heart disease and two due to primary disease. Voice quality was 
assessed through telephonic interview with patients having intact 
larynx. About two-third of the patients were satisfied with their 
voice quality.
Table 3: Patterns of failure
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(BIR) trial.[10,29,30] In our study, only 7 of 87 patients (8%) 
failed locally which account for 82% local control rate 
that is in contrast with published international literature.
The optimum beam energy advocated for the management 
of early glottic carcinoma is cobalt-60 or 4 MV photons.[17] 
The rationale for using lower beam energy is the fact that 
high-energy photons have increased penetrating power 
that causes inadequate build-up in the anterior commissure 
due to thin wedge shape of the midline of the neck that lead 
to underdose of tumour. Dosimetry studies to calculate the 
degree of underdosage have yielded conflicting results. 
The dose absorbed in the anterior commissure decreased 
by 12% with 6 MV photons and 18% with 10 MV photons 
when compared with cobalt-60.[31] Akaine et al. reported 
on 154 patients with Stage T1 tumours treated with 6 MV; 
the 5-year local control rate with and without anterior 
commissure involvement was 81% (27 patients) and 91% 
(127 patients), respectively. While the result did not reach 
statistical significance, it does invoke clinical concern.[32] 
Conversely, data from other retrospective studies suggest 
that the estimated 5-year local control rates with 6, 8 and 
10 MV photons may be similar to those achieved with 
cobalt-60.[28]
Various studies have indicated that endoscopic laser 
excision produces oncologic outcome and voice quality 
comparable to RT treatment.[33] While radiation is often 
favoured as it appears to be associated with reduced 
impairment of voice quality, but qualitative studies about 
vocal function in post-irradiated patients have been 
inconclusive and not uniform.[34-36] Dinapoli et al. reported 
on 143 patients with T1 glottis cancer; 73 underwent 
surgery and 70 underwent RT. No statistically significant 
differences were found between the two groups in terms 
of OS and disease-free survival, and better scores for voice 
quality were found for patients receiving RT compared to 
surgery.[37,38] In our study, there was no formal assessment 
of voice. Telephonic interview was done with patients 
having intact larynx. About two-third of the patients were 
satisfied with their voice quality.
There are several limitations for this study. First, our 
study is a single institutional retrospective review 
spanning over one decade. The second limitation includes 
availability of only subjective measurement of patient and 
physician-reported voice quality measures. Finally, as all 
of our patients received treatment with two-dimensional 
planning system, tumour volume and tumour volume 
dosimetry are better captured in modern three-dimensional 
treatment techniques.
Conclusion
Hypofractionated RT 55 Gy in 20 fractions seems to 
achieve good OS for T1–T2 N0 glottis squamous cell 
carcinoma with good voice preservation.
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